We facilitate a continuous flow of medical innovation on our platform, seeking out and connecting with entrepreneurs and innovators from every corner of the globe.
Cutting-edge innovation in California with a strong community that includes top universities, institutes, and VCs
World-class expertise in engineering and manufacturing
World leader in clinical trials
World’s second largest MedTech market with USD 100B in 2024, a vibrant capital market eager to invest in healthcare innovation
Engineering talent and leadership in MedTech innovation
A sophisticated capital market, highly respected business and legal environment, and strong government support for innovation
R&D never stops at our own integrated facilities as well as with partners around the world. We are utterly relentless; we understand that getting critical MedTech and hospital supplies where they’re needed isn’t just a market advantage: it saves lives.
We make interventional neurovascular products available through our subsidiary Minitech Medical; R&D, manufacturing, and distribution for a wider range of interventional devices will commence at our own integrated facility in Wuxi, Jiangsu province by 2025. By 2027, its Annual Output Value is expected to reach more than USD 700M.
Our subsidiary Reach Surgical is the largest local minimally invasive surgical enterprise in China, with integrated facilities for R&D, manufacturing, and distribution for stapler and ultrasonic energy devices.
Whichever stage of development your company or product is at—welcome aboard. Diverse and flexible partnership models work to bring out the best in your technology as soon as possible.
Our open innovation platform welcomes R&D groups from around the world to collaborate with and innovate for APAC markets. Our accelerator setup and Singapore HQ are open to incubating the most promising IPs into first-in-class medical technology for today’s most urgent health issues. Our strategic partnerships with global leading-edge R&D groups help overcome technical hurdles, making the road to innovation a fast one.
Our platform is truly regional, backed by leading investors in Asia with cross-industry leverage and access to substantial financing. This allows us to help our partners gain access to the capital market network for deal syndication and co-investment.
We help our partners navigate APAC markets by providing market insights and competitive strategies based on Voice of Customer and Key Opinion Leader engagement in the region.
The solid expertise of our own in-house regulatory team expedites product registration and approval.
The team also advises on medical device strategies for NMPA, PMDA, and ASEAN countries and executes prototype testing, ethics committee submissions, clinical trials, and final product registration and approvals.
We have our own in-house market access team for reimbursement, tenders, and hospital listing, a regulatory and market access team with over 30 experts, and an experienced government affairs team supported by leading investors.
In China, our sales force comprises of 1,500 sales reps covering well over 4,000 hospitals and clinics. Our aim is to scale up to 10,000 reps covering 15,000 hospitals and clinics in five years. We have also made substantial investments into IT towards developing transparent, real-time, end-to-end transactions with strong compliance management to safeguard our business conduct.
Upon completion, our manufacturing campuses will both be scalable and strategically located, with one in Tianjin near Beijing and the other, in Wuxi near Shanghai.
Our open platform welcomes companies that meet strong market needs in emerging economies, leading to the acquisitions and integration that continuously expand our repertoire of value-based healthcare.
Here is where tomorrow’s technology begins—in collaboration with companies whose device innovations show great promise to significantly improve healthcare.
Incubation happens typically over a three-to-five-year development period prior to commercialisation. This grows our value-based therapy portfolio and leads to exciting developments in the MedTech industry.
We cover over 4,000 hospitals and private clinics in China and are on track to covering 15,000 hospitals and clinics in five years.
Made possible by key subsidiaries Uniwin and Bluepower, together, we achieve unprecedented efficiency, transparency, and scale for our partners, suppliers, and subsidiaries.
With more than 500 Centres of Excellence and 3,500 major hospitals in our care, our network goes beyond sales and distribution.
We drive the adoption of new and innovative therapies, thanks to strong clinical support
We put in place a patient referral and management network between major and county hospitals
We strengthen collaboration with physicians, fostering innovation in the long term
Our distributorship model focuses on
Product mix serving market needs
Partnerships with local distributors
National Contract Sales Organisation network with professional go-to market capabilities
Online education platforms and offline road shows
Sizable and scalable field force
Uniwin Academy for sales training
Sales Force Effectiveness management
Regular clinical training